Physician profile
Robert Lee
NPI 1801180807
$9,124.97
in general payments reported to CMS, 2019-2025
35 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $1,097 · 2021: $1,172 · 2022: $920 · 2023: $1,380 · 2024: $1,525 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,025 · Education: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,024.77 |
| Education | $552.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,141.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $957.99 | 2019-2025 | |
| Janssen Biotech, INC. | $930.10 | 2019-2025 | Tremfya |
| Intuitive Surgical, INC. | $900.00 | 2021 | |
| Lilly USA, LLC | $788.22 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $778.70 | 2019-2025 | Ilumya |
| Leo Pharma INC. | $520.69 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $494.40 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $382.82 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $318.78 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $305.59 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $260.68 | 2020-2025 | Dupixent |
| Genzyme Corporation | $246.47 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $135.57 | 2020-2025 | |
| Organogenesis INC. | $128.12 | 2023-2025 | Puraply, Cygnus Dual, Via Matrix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $108.50 | 2019-2024 | |
| Biofrontera INC. | $104.75 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Scientific Affairs, LLC | $67.87 | 2019 | |
| Dermavant Sciences, INC. | $59.61 | 2022-2023 | Vtama |
| Epi Health, LLC | $54.60 | 2019-2022 | |
| Almirall LLC | $54.54 | 2019-2025 | Seysara |
| Mayne Pharma Commercial LLC | $53.29 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $50.78 | 2022 | |
| Arcutis Biotherapeutics, INC. | $43.53 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $41.03 | 2023 | |
| Medtronic, INC. | $32.62 | 2022-2023 | Closurefast |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.11 | 2019 | |
| Celgene Corporation | $23.57 | 2019 | |
| Blueprint Medicines Corporation | $20.74 | 2023 | |
| Mylan Pharmaceuticals INC. | $20.36 | 2019 | |
| Bausch & Lomb Americas INC. | $18.68 | 2025 | Xiidra |
| Amgen INC. | $18.30 | 2020 | |
| Strata Skin Sciences, INC. | $15.78 | 2025 | Xtrac |
| Convatec INC. | $14.41 | 2025 | |
| Organon LLC | $5.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.